King's College London

Research portal

The therapeutic potential of targeting chemokine signalling in the treatment of chronic pain

Research output: Contribution to journalArticle

Standard

The therapeutic potential of targeting chemokine signalling in the treatment of chronic pain. / Montague, Karli; Malcangio, Marzia.

In: Journal of Neurochemistry, 24.02.2017.

Research output: Contribution to journalArticle

Harvard

Montague, K & Malcangio, M 2017, 'The therapeutic potential of targeting chemokine signalling in the treatment of chronic pain', Journal of Neurochemistry. https://doi.org/10.1111/jnc.13927

APA

Montague, K., & Malcangio, M. (2017). The therapeutic potential of targeting chemokine signalling in the treatment of chronic pain. Journal of Neurochemistry. https://doi.org/10.1111/jnc.13927

Vancouver

Montague K, Malcangio M. The therapeutic potential of targeting chemokine signalling in the treatment of chronic pain. Journal of Neurochemistry. 2017 Feb 24. https://doi.org/10.1111/jnc.13927

Author

Montague, Karli ; Malcangio, Marzia. / The therapeutic potential of targeting chemokine signalling in the treatment of chronic pain. In: Journal of Neurochemistry. 2017.

Bibtex Download

@article{2e92f7df8ddd4d34b5e8493838ed36aa,
title = "The therapeutic potential of targeting chemokine signalling in the treatment of chronic pain",
abstract = "Chronic pain is a distressing condition, which is experienced even when the painful stimulus, whether surgery or disease related, has subsided. Current treatments for chronic pain show limited efficacy and come with a host of undesirable side-effects, and thus there is a need for new, more effective therapies to be developed. The mechanisms underlying chronic pain are not fully understood at present, although pre-clinical models have facilitated the progress of this understanding considerably in the last decade. The mechanisms underlying chronic pain were initially thought to be neurocentric. However, we now appreciate that non-neuronal cells play a significant role in nociceptive signalling through their communication with neurons. One of the major signalling pathways, which mediates neuron/non-neuronal communication, is chemokine signalling. In this review, we discuss selected chemokines that have been reported to play a pivotal role in the mechanisms underlying chronic pain in a variety of pre-clinical models. Approaches that target each of the chemokines discussed in this review come with their advantages and disadvantages; however, the inhibition of chemokine actions is emerging as an innovative therapeutic strategy, which is now reaching the clinic, with the chemokine Fractalkine and its CX3CR1 receptor leading the way. This article is part of the special article series {"}Pain{"}.",
keywords = "Chemokines, Chronic pain, Proteases, Therapy",
author = "Karli Montague and Marzia Malcangio",
note = "{\textcopyright} 2016 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.",
year = "2017",
month = feb,
day = "24",
doi = "10.1111/jnc.13927",
language = "English",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - The therapeutic potential of targeting chemokine signalling in the treatment of chronic pain

AU - Montague, Karli

AU - Malcangio, Marzia

N1 - © 2016 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.

PY - 2017/2/24

Y1 - 2017/2/24

N2 - Chronic pain is a distressing condition, which is experienced even when the painful stimulus, whether surgery or disease related, has subsided. Current treatments for chronic pain show limited efficacy and come with a host of undesirable side-effects, and thus there is a need for new, more effective therapies to be developed. The mechanisms underlying chronic pain are not fully understood at present, although pre-clinical models have facilitated the progress of this understanding considerably in the last decade. The mechanisms underlying chronic pain were initially thought to be neurocentric. However, we now appreciate that non-neuronal cells play a significant role in nociceptive signalling through their communication with neurons. One of the major signalling pathways, which mediates neuron/non-neuronal communication, is chemokine signalling. In this review, we discuss selected chemokines that have been reported to play a pivotal role in the mechanisms underlying chronic pain in a variety of pre-clinical models. Approaches that target each of the chemokines discussed in this review come with their advantages and disadvantages; however, the inhibition of chemokine actions is emerging as an innovative therapeutic strategy, which is now reaching the clinic, with the chemokine Fractalkine and its CX3CR1 receptor leading the way. This article is part of the special article series "Pain".

AB - Chronic pain is a distressing condition, which is experienced even when the painful stimulus, whether surgery or disease related, has subsided. Current treatments for chronic pain show limited efficacy and come with a host of undesirable side-effects, and thus there is a need for new, more effective therapies to be developed. The mechanisms underlying chronic pain are not fully understood at present, although pre-clinical models have facilitated the progress of this understanding considerably in the last decade. The mechanisms underlying chronic pain were initially thought to be neurocentric. However, we now appreciate that non-neuronal cells play a significant role in nociceptive signalling through their communication with neurons. One of the major signalling pathways, which mediates neuron/non-neuronal communication, is chemokine signalling. In this review, we discuss selected chemokines that have been reported to play a pivotal role in the mechanisms underlying chronic pain in a variety of pre-clinical models. Approaches that target each of the chemokines discussed in this review come with their advantages and disadvantages; however, the inhibition of chemokine actions is emerging as an innovative therapeutic strategy, which is now reaching the clinic, with the chemokine Fractalkine and its CX3CR1 receptor leading the way. This article is part of the special article series "Pain".

KW - Chemokines

KW - Chronic pain

KW - Proteases

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85013782481&partnerID=8YFLogxK

U2 - 10.1111/jnc.13927

DO - 10.1111/jnc.13927

M3 - Article

C2 - 27973687

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454